Roche (OTCMKTS:RHHBY) Hits New 12-Month High – Should You Buy?

Roche Holding AG (OTCMKTS:RHHBY) shares hit a new 52-week high during mid-day trading on Monday. The stock traded as high as $61.51 and last traded at $61.51, with a volume of 503,200 shares changing hands. The stock had previously closed at $59.37.

Analyst Ratings Changes

Several equities analysts recently issued reports on RHHBY shares. Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. HSBC reissued a “hold” rating on shares of Roche in a report on Thursday, September 10th. UBS Group downgraded shares of Roche from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price on the stock in a research note on Friday, August 7th. Finally, Royal Bank Of Canada initiated coverage on shares of Roche in a research report on Tuesday, September 8th. They set an “outperform” rating for the company. Eight investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Roche has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Roche Trading Up 4.0%

The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $55.86 and a 200-day simple moving average of $53.88.

Institutional Trading of Roche

A number of hedge funds have recently modified their holdings of the company. McIlrath & Eck LLC bought a new stake in Roche in the first quarter valued at approximately $39,000. Renasant Bank bought a new position in shares of Roche during the second quarter worth $210,000. Woodstock Corp bought a new position in shares of Roche during the third quarter worth $245,000. Enterprise Financial Services Corp grew its holdings in shares of Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after buying an additional 345 shares during the period. Finally, Archer Investment Corp grew its holdings in shares of Roche by 7.7% in the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock valued at $278,000 after buying an additional 398 shares during the period.

Roche Company Profile

Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions.

Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.

Headquartered in Basel, Roche operates in markets around the world.